Efforts in minimizing risk of viral transmission through viral inactivation

Annals of Medicine

Volumn 32, Issue 7, 2000, Pages 475-484

  Horowitz, B ^a   Ben Hur, E ^a  

^a LLC ^*  (United States)

Author keywords

AIDS; Blood; Hepatitis; Viral safety; Virus inactivation

Indexed keywords

4' AMINOMETHYL 4,5',8 TRIMETHYLPSORALEN; AMOTOSALEN; ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; HEPARIN; IODINE; METHYLENE BLUE; PEN 110; PHOTOSENSITIZING AGENT; PSORALEN; PSORALEN DERIVATIVE; RIBOFLAVIN; RUTOSIDE; S 303; SEPHADEX; THIOBUTABARBITAL; THIONINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD FILTRATION; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; GAMMA IRRADIATION; GOOD LABORATORY PRACTICE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; LABORATORY TEST; NANOFILTRATION; NONHUMAN; PASTEURIZATION; PHASE 3 CLINICAL TRIAL; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; SCREENING TEST; SIDE EFFECT; ULTRAVIOLET IRRADIATION; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 0033756819     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890009002023     Document Type: Article

References (83)

1. Protecting the nation's blood supply from infectious agents: The need for new standards to meet new threats
2. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent
3. Human parvovirus B19 and blood products
4. Hepatitis A virus (HAV) and parvovirus B19 in donor blood
5. Large-scale screening for human parvovirus B19 DNA by PCR: Application for the quality control of plasma for fractionation
6. Bacterial contamination of cellular blood components. A retrospective review at a large cancer center
7. Transfusion-transmitted Yersinia enterocolitica infection in New Zealand
8. Reassessment of blood donor selection criteria for United States travelers to malarious areas
9. Specific antibodies to Trypanosoma cruzi among blood donors
10. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors
11. The risk of transfusion-transmitted viral infections
12. The development of virus-free labile blood derivatives
13. Virucidal treatment of clotting factor concentrates
14. Inactivation of viruses in blood and plasma products
15. Viral safety of solvent-detergent treated blood products
16. GB virus C/hepatitis G virus and intravenous immunoglobulins
17. Persistent parvovirus B19 infections in humans
18. Chromatographic removal of viruses from plasma derivatives
19. Removal and inactivation of hepatitis A. Virus (HAV) during processing of factor VIII concentrates
20. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses
21. Hepatitis A virus infections associated with clotting factor concentrate in the United States
22. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography
23. Inactivation and removal of human immunodeficiency virus in monoclonal purified antihemophilic factor (human) (Hemophil M)
24. Removal of viral contaminants by monoclonal antibody purification of plasma proteins
25. Preclinical characterization of a new pasteurized monoclonal antibody purified factor VIIIC
26. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate
27. A novel method for removal of human immunodeficiency virus: Filtration with porous polymeric membranes
28. Nanofiltration, a new specific virus elimination method applied to high purity factor IX and factor XI concentrates
29. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration
30. Viral validation of factor VIII SD-35-15 filtration step
31. VIII SD-35-15: Filtration step study
32. A solvent/detergent treated, pasteurised and highly purified factor VIII concentrate
33. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurization
34. 'In vitro' and in animal model studies on a double virus-inactivated factor VIII concentrate
35. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C
36. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates
37. Transmission of human parvovirus B19 by coagulation factor concentrates
38. No induction of factor VIII inhibitors in hemophilia A patients treated with Hemoctin SDH (PD FVIII, double virus inactivated)
39. Plasma-derived, solvent-detergent treated antihemophilic factor (AHF) with an additional 80 °C final container dry heat step lacks immunogenicity and retains safety and efficacy in HIV-negative subjects with hemophilia A (HA)
40. The physical state of viral nucleic acid and the sensitivity of viruses to ultraviolet light
41. Inactivation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin
42. Validation of a continuous flow device for UV-C virus inactivation process at production scale
43. Virucidal UVC treatment of plasma and factor VIII concentrate: Protection of proteins by antioxidants
44. Virucidal treatment of blood protein products with UVC
45. Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors
46. Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins
47. New methods for inactivation of lipid-enveloped and non-enveloped viruses
48. Viral inactivation of vesicular stomatitis virus in normal human serum by cross-linked polyvinylpyrrolidone
49. Inactivation of lipid-enveloped and non-lipid-enveloped model viruses in normal human plasma by crosslinked starch-iodine
50. Solvent/detergent-treated plasma: A virus inactivated substitute for fresh frozen plasma
51. Virus inactivation by solvent/detergent treatment and the manufacture of SD-Plasma
52. Development of a universal solvent-detergent treated plasma
53. Photodynamic inactivation of animal viruses: A review
54. The role of DNA damage in PM2 viral inactivation by methylene blue photosensitization
55. Analysis of viral DNA, protein and envelope damage after methylene blue, phthalocyanine derivative or merocyanine 540 photosensitization
56. Photo-inactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light
57. Differential sensitivities of viruses in red cells suspensions to methylene blue photosensitization
58. Photodynamic virus inactivation of blood components
59. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma
60. Initial experiences with methylene blue virus inactivated fresh frozen plasma: Results of a clinical and in vitro study
61. No evidence for neoantigens in human plasma after photochemical virus inactivation
62. Mammalian genotoxicity assessment of methylene blue in plasma: Implications for virus inactivation
63. Virally inactivated fresh frozen plasma transfusion in normal volunteers
64. A pasteurized therapeutic plasma
65. Photodynamic virus inactivation of thrombocyte concentrates by phenothiazine dyes
66. Thionine/light for virus inactivation of platelet concentrates
67. The use of riboflavin for the inactivation of pathogens in blood products
68. Photochemistry and photobiology of furocoumarins (psoralens)
69. Quencher enhanced specificity of psoralens photosensitized viral inactivation in platelet concentrates
70. Inactivation of Trypanosoma cruzi trypomastigote forms in blood components with a Psoralen and Ultraviolet A light
71. Photochemical inactivation of pathogenic bacteria in human platelet concentrates
72. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long wavelength ultraviolet light
73. Post-infusion recovery and survival of photochemically treated (PCT) platelets
74. Inactivation of multiple forms of human immunodeficiency virus in red cell concentrates by phthalocyanine photosensitization
75. Inactivation of Trypanosoma cruzi trypomastigote forms in blood components by photodynamic treatment with phthalocyanines
76. Photosensitized inactivation of Plasmodium falciparum in human erythrocytes by phthalocyanines
77. Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue
78. Importance of type I and type II mechanisms in the photodynamic inactivation of viruses in blood with aluminum phthalocyanine derivatives
79. Virus inactivation in red cell concentrates by photo-sensitization with phthalocyanines: Protection of red cells but not of vesicular stomatitis virus with a water-soluble analog of vitamin E
80. In vivo analysis of packed red blood cells treated with S-303 to inactivate pathogens
81. Viability of red blood cells treated with a novel pathogen inactivation system
82. Inactine: A method for viral inactivation in red blood cell concentrate
83. Viral inactivation in red blood cell concentrates by Inactine: Mechanism of action and lack of effect on red cell physiology